The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
Abstract
Purpose: Single-agent doxorubicin remains the standard treatment for advanced soft tissue sarcomas. Combining doxorubicin with standard-dose ifosfamide has not been shown to improve survival and is associated with a significantly increased toxicity; it is not known whether higher dose single-agent ifosfamide is superior to doxorubicin. Patients and Methods: This randomized prospective multicenter phase III trial was designed to compare progression-free survival of patients with advanced soft tissue sarcoma receiving either regimen of standard doxorubicin 75 mg/m 2 every 21 days, ifosfamide 9 g/m 2 over 3 days continuous infusion, or ifosfamide 3 g/m 2 per day in 3 hours over 3 days. The primary end point was progression-free survival. Secondary end points included overall survival, response rate, and toxicity. Results: The study included 326 patients. Grade 4 leukopenia, neutropenia, febrile neutropenia, and encephalopathy were more frequent in the ifosfamide arms. Progression-free survival, overall survival, and response rates were not significantly different between the three arms. An independent data monitoring committee reviewed the interim data and recommended early closure of the trial for futility (ie, no significant difference would be shown). Conclusion: Single-agent doxorubicin remains the treatment of choice for patients with advanced soft tissue sarcoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Self-citationThe cochrane database of systematic reviews
Geddes, J. (1996) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(96)90063-x · Cited by 5,989
Verweij, J., Casali, P. G., Zalcberg, J., LeCesne, A., Reichardt, P., Blay, J.-Y., Issels, R., van Oosterom, A., Hogendoorn, P. C., Van Glabbeke, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17098-0 · Cited by 1,665
Self-citationGemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial
Hensley, M. L., Maki, R., Venkatraman, E., Geller, G., Lovegren, M., Aghajanian, C., Sabbatini, P., Tong, W., Barakat, R., & Spriggs, D. R. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.050 · Cited by 683
Van Glabbeke, M., van Oosterom, A. T., Oosterhuis, J. W., Mouridsen, H., Crowther, D., Somers, R., Verweij, J., Santoro, A., Buesa, J., & Tursz, T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.150 · Cited by 608
Self-citationSantoro, A., Tursz, T., Mouridsen, H., Verweij, J., Steward, W., Somers, R., Buesa, J., Casali, P., Spooner, D., & Rankin, E. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1537 · Cited by 526
Self-citationEdmonson, J. H., Ryan, L. M., Blum, R. H., Brooks, J. S., Shiraki, M., Frytak, S., & Parkinson, D. R. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.7.1269 · Cited by 516
Antman, K. H., Crowley, J. J., Balcerzak, S. P., Rivkin, S. E., Weiss, G. R., ELIAS, A. D., Natale, R. B., Cooper, R. M., Barlogie, B., & Trump, D. L. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.7.1276 · Cited by 478
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
Van Glabbeke, M., Verweij, J., Judson, I., & Nielsen, O. S. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00398-7 · Cited by 424
Self-citationJudson, I., Radford, J. A., Harris, M., Blay, J.-Y., van Hoesel, Q., le Cesne, A., van Oosterom, A. T., Clemons, M. J., Kamby, C., Hermans, C., et al. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00050-8 · Cited by 392
Self-citationOmura, G. A., Major, F. J., Blessing, J. A., Sedlacek, T. V., Thigpen, J. T., Creasman, W. T., & Zaino, R. J. (1983) · Cancer · doi:10.1002/1097-0142(19830815)52:4<626::aid-cncr2820520409>3.0.co;2-e · Cited by 355
Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas.
Borden, E. C., Amato, D. A., Rosenbaum, C., Enterline, H. T., Shiraki, M. J., Creech, R. H., Lerner, H. J., & Carbone, P. P. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.6.840 · Cited by 299
Patel, S. R., Vadhan-Raj, S., Papadopolous, N., Plager, C., Burgess, M. A., Hays, C., & Benjamin, R. S. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2378 · Cited by 257
Le Cesne, A., Judson, I., Crowther, D., Rodenhuis, S., Keizer, H. J., Van Hoesel, Q., Blay, J. Y., Frisch, J., Van Glabbeke, M., Hermans, C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.14.2676 · Cited by 256
Self-citationBlay, J.-Y., van Glabbeke, M., Verweij, J., van Oosterom, A. T., Le Cesne, A., Oosterhuis, J. W., Judson, I., & Nielsen, O. S. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00480-x · Cited by 184
Self-citationvan Oosterom, A. T., Mouridsen, H. T., Nielsen, O. S., Dombernowsky, P., Krzemieniecki, K., Judson, I., Svancarova, L., Spooner, D., Hermans, C., Van Glabbeke, M., et al. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00491-4 · Cited by 164
Self-citationPinedo, H. M., Bramwell, V. H. C., Mouridsen, H. T., Somers, R., Vendrik, C. P. J., Santoro, A., Buesa, J., Wagener, T., van Oosterom, A. T., Unnik, J. A. M. V., et al. (1984) · Cancer · Cited by 129
Nielsen, O. S., Dombernowsky, P., Mouridsen, H. T., Crowther, D., Verweij, J., Buesa, J., Steward, W. P., Daugaard, S., Glabbeke, M. M. V., Kirkpatrick, A., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.735 · Cited by 105
Self-citationSingle-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience.
Benjamin, R. S., Legha, S. S., PATEL, S. R., et al. (1993) · PubMed · Cited by 85
Bezwoda, W. R., Derman, D. P., de Moor, N. G., Lange, M., & Levin, J. (1982) · Cancer · doi:10.1002/1097-0142(19821215)50:12<2757::aid-cncr2820501211>3.0.co;2-j · Cited by 35
Cited by
Casali, P. G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brodowicz, T., Broto, J. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy096 · Cited by 1,614
Self-citation(2014) · Annals of Oncology · doi:10.1093/annonc/mdu254 · Cited by 656
Seddon, B., Strauss, S. J., Whelan, J., Leahy, M., Woll, P. J., Cowie, F., Rothermundt, C., Wood, Z., Benson, C., Ali, N., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30622-8 · Cited by 528
Self-citationChawla, S. P., Cranmer, L. D., Van Tine, B. A., Reed, D. R., Okuno, S. H., Butrynski, J. E., Adkins, D. R., Hendifar, A. E., Kroll, S., & Ganjoo, K. N. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3660 · Cited by 155
Luke, J. J., D'Adamo, D. R., Dickson, M. A., Keohan, M. L., Carvajal, R. D., Maki, R. G., de Stanchina, E., Musi, E., Singer, S., & Schwartz, G. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3203 · Cited by 95
Metadata
- Authors
- Lorigan, P., Verweij, J., Papai, Z., Rodenhuis, S., Le Cesne, A., Leahy, M. G., Radford, J. A., Van Glabbeke, M. M., Kirkpatrick, A., Hogendoorn, P. C. W., & Blay, J.-Y.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-07-20
- Volume
- 25
- Issue
- 21
- Pages
- 3144-3150
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2160752563
- Cited by
- 256
- References
- 20
- FWCI
- 9.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.